Paul F. Vogel has announced his retirement as Chairman of the Board of Lachman Consultants, effective March 31, 2017. Paul plans to spend more time with family and his many personal interests, following a 44-year career that included 21 years at the U.S. Food and Drug Administration followed by 23 years at Lachman Consultants. Richard S. Bowles, III, Ph.D., will join Lachman Consultants as its new Chairman of the Board on April 1, 2017.
“I am very fortunate to have had the opportunity to serve the U.S. FDA and Lachman Consultants, working with the international industry in assuring the availability of safe, effective and quality pharmaceuticals, biologics and medical devices meeting appropriate standards. I am especially pleased that Dr. Richard Bowles will be our new Chairman of the Board. Rick has an exceptional reputation based on his > 40-year career at major global companies, where he held management and high-level executive positions in the areas of manufacturing, technology, development, and corporate quality and compliance. In his last position, at Merck, Rick was Executive Vice President / Chief Ethics & Compliance Officer, Member of the Executive Committee, and a management Member of the Board of Directors’ Audit Committee. At Schering-Plough, Rick served as Vice President of Pharmaceutical Manufacturing, followed by Senior Vice President, Global Quality Operations, where he earned the respect of the industry and regulators by strengthening standards and assurance of product quality and compliance. As Lachman’s new Chairman of the Board, Rick will work closely with the Board, in setting the vision, strategy and governance of the company. Rick also will serve as a key resource to Fran Zipp – President and CEO, other company management, and clientele. Lachman Consultants is well positioned to continue its reputation as the premier ‘full service” consulting company in this space.” …. Paul Vogel
Lachman Consultants’ wishes Paul the very best in his retirement, and welcomes Dr. Bowles to his new role.
